Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

British journal of cancer·2026
Same author

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal for immunotherapy of cancer·2026
Same author

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
06:46

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

2.3K

Vemurafenib.

Claus Garbe1, Sail Abusaif, Thomas K Eigentler

  • 1Department of Dermatology, University Medical Centre, Liebermeisterstr 25, 72074, Tuebingen, Germany, claus.garbe@med.uni-tuebingen.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|April 24, 2014
PubMed
Summary
This summary is machine-generated.

Vemurafenib effectively targets BRAF V600E mutations in melanoma, showing high response rates and improved survival. However, resistance and side effects like skin cancers remain challenges, prompting research into combination therapies.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Related Experiment Videos

Last Updated: Apr 30, 2026

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
06:46

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

2.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF V600E mutations activate the MAPK pathway in ~40% of melanoma patients, driving proliferation and inhibiting apoptosis.
  • The RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway is crucial in melanoma pathogenesis.
  • BRAF V600K mutations are found in ~5% of melanoma cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of vemurafenib, a BRAF inhibitor, in melanoma patients with BRAF V600E mutations.
  • To investigate vemurafenib's impact on tumor regression, survival, and potential resistance mechanisms.
  • To explore vemurafenib's therapeutic potential in other BRAF-mutated solid tumors.

Main Methods:

  • Preclinical studies in animal models with BRAF V600E mutated cells.
  • Phase I, II, and III clinical trials in patients with unresectable metastatic melanoma harboring BRAF V600E mutations.
  • Biochemical assays to assess vemurafenib's binding affinity and inhibitory activity on BRAF-V600E kinase.

Main Results:

  • Vemurafenib demonstrated potent inhibition of ERK phosphorylation and cell proliferation in BRAF-mutant cell lines.
  • Animal models showed tumor regressions in BRAF V600E mutated cells treated with vemurafenib.
  • Clinical trials reported high objective response rates (50-80%), prolonged progression-free survival (7 vs. 2 months), and overall survival (14 vs. 9 months) compared to dacarbazine.
  • Approximately 25% of patients developed keratoacanthoma-type skin cancers; resistance developed in the majority of patients over time.

Conclusions:

  • Vemurafenib is an effective targeted therapy for BRAF V600E-mutated melanoma, significantly improving patient outcomes.
  • Development of resistance and specific side effects like skin cancers are key challenges requiring further investigation.
  • Combination therapies involving vemurafenib with other inhibitors or immunotherapies may enhance its therapeutic potential in melanoma and other BRAF-mutated cancers.